Jade Biosciences' JADE101 Shows 70% IgA Reduction in Phase 1, Targets Best-in-Class IgAN Therapy
JBIO has more than doubled off its 52-week low of $6.565 on elevated volume (1.9× avg).
Summary
Jade Biosciences reported strong interim Phase 1 results for JADE101 in IgA Nephropathy, demonstrating approximately 70% IgA reductions sustained at 12 weeks and a favorable safety profile. The company is positioning JADE101 as a potential best-in-class therapy with convenient every-12-week dosing. This positive clinical update is highly significant, especially given the company's recent filings for a $200 million ATM offering and a $600 million universal shelf registration to address rising losses. Advancing JADE101 to Phase 2, with a Phase 3 trial planned for the first half of 2027, provides a clear path forward for this key asset.
At the time of this announcement, JBIO was trading at $22.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $6.57 to $28.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.